-
摘要:
前列腺癌（prostate cancer, PCa）骨转移的发生率很高，不仅引发疼痛、增加骨相关事件的风险，还严重影响患者的生活质量以及缩短其生存期。近年来，随着对PCa骨转移机制以及肿瘤细胞和骨微环境之间相关调控作用的认知不断深入，许多新药被开发和批准用于抑制骨转移的“恶性循环”，减少骨转移引起的并发症，使PCa骨转移治疗取得重大进展。本文从PCa骨转移机制、骨靶向药物治疗和非骨特异性抗癌药物治疗研究进展方面进行综述，以期为临床医生提供更多的治疗选择。
Abstract:The incidence of bone metastases is relatively high in prostate cancer (PCa) patients. Bone metastases not only cause pain and increase the risk of skeletal related events (SREs), but also have a significant impact on quality of life and shorten the overall survival of patients. In recent years, with the further understanding of the mechanism of bone metastases and the cross-talk between tumor cells and bone microenvironment, many new effective drugs have been developed and approved to inhibit the "vicious cycle" of bone metastases. The complications caused by bone metastases are reduced, which led to significant advances in the treatment of PCa bone metastasis. In this paper, we review the mechanism of PCa bone metastases, bone-targeting agents and non-bone specific anticancer drugs therapies.
-
Key words:
- Prostate cancer /
- Bone metastases /
- Treatment /
- Advances
-
作者贡献李宁：文献查阅，论文设计、撰写及修改肖国有：论文的设计、指导和审校
-
[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018[J]. CA: A Cancer J Clin, 2018, 68: 7-30. doi: 10.3322/caac.21442
[2] 陈锐, 谢立平, 周利群, 等.中国前列腺癌联盟成员医院前列腺穿刺活检现状的调查报告[J].中华泌尿外科杂志, 2015, 36(5): 342-345. http://d.wanfangdata.com.cn/Periodical/zhmnwk201505006 Chen R, Xie LP, Zhou LQ, et al. Current status of prostate biopsy in Chinese Prostate Cancer Consortium member hospitals[J]. Zhonghua Mi Niao Wai Ke Za Zhi, 2015, 36(5): 342-345. http://d.wanfangdata.com.cn/Periodical/zhmnwk201505006
[3] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34. doi: 10.3322/caac.21551
[4] Zhong Y, Valderrama A, Yao J, et al. Economic Evaluation of Treating Skeletal-Related Events among Prostate Cancer Patients[J]. Value Health, 2018, 21(3): 304-309. doi: 10.1016/j.jval.2017.02.008
[5] Pereira J, Body JJ, Gunther O, et al. Cost of skeletal complications from bone metastases in six European countries[J]. J Med Econ, 2016, 19(6): 611-618. doi: 10.3111/13696998.2016.1150852
[6] Akaza H, Procopio G, Pripatnanont C, et al. Metastatic castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy: treatment patterns from the PROXIMA prospective registry[J]. J Glob Oncol, 2018, 4: 1-12. http://www.researchgate.net/publication/327941511_Metastatic_Castration-Resistant_Prostate_Cancer_Previously_Treated_With_Docetaxel-Based_Chemotherapy_Treatment_Patterns_From_the_PROXIMA_Prospective_Registry
[7] Hegemann M, Maas M, Rausch S, et al. Current concepts and trends in the treatment of bone metastases in patients with advanced prostate cancer[J]. Asian J Androl, 2019, 21(1): 12-18. doi: 10.4103/aja.aja_59_17
[8] Berish RB, Ali AN, Telmer PG, et al. Translational models of prostate cancer bone metastasis[J]. Nat Rev Urol, 2018, 15(7): 403-421. doi: 10.1038/s41585-018-0020-2
[9] Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer[J]. Nat Rev Mol Cell Biol, 2019, 20(2): 69-84. http://www.ncbi.nlm.nih.gov/pubmed/30459476
[10] Gupta N, Duda DG. Role of stromal cell-derived factor 1α pathway in bone metastatic prostate cancer[J]. J Biomed Res, 2016, 30(3): 181-185. http://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CJFD&filename=NJYY201603003
[11] Sottnik JL, Daignault-Newton S, Zhang X, et al. Integrin alpha2beta1 (α2β1) promotes prostate cancer skeletal metastasis[J]. Clin Exp Metastasis, 2013, 30(5): 569-578. doi: 10.1007/s10585-012-9561-6
[12] Hall CL, Daignault SD, Shah RB, et al. Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis[J]. Prostate, 2008, 68(13): 1396-1404. doi: 10.1002/pros.20805
[13] Walz S, Maas M, Stenzl A, et al. Bone health issues in patients with prostate cancer: an evidence-based review[J]. World J Mens Health, 2019, 38(2): 151-163. http://www.researchgate.net/publication/332905327_Bone_Health_Issues_in_Patients_with_Prostate_Cancer_An_Evidence-Based_Review
[14] Qayoom I, Raina DB, Širka A, et al. Anabolic and antiresorptive actions of locally delivered bisphosphonates for bone repair[J]. Bone Joint Res, 2018, 7(10): 548-560. http://www.researchgate.net/publication/328051886_Anabolic_and_antiresorptive_actions_of_locally_delivered_bisphosphonates_for_bone_repair_A_review
[15] Soares AP, do Espirito Santo RF, Sérgio Roberto Peres Line, et al. Bisphosphonates: pharmacokinetics, bioavailability, mechanisms of action, clinical applications in children, and effects on tooth development[J]. Environ Toxicol Pharmacol, 2016, 42: 212-217. doi: 10.1016/j.etap.2016.01.015
[16] James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial[J].Lancet, 2016, 387(10024): 1163-1177. doi: 10.1016/S0140-6736(15)01037-5
[17] Smith MR, Halabi S, Ryan CJ, et al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)[J]. J Clin Oncol, 2014, 32(11): 1143-1150. doi: 10.1200/JCO.2013.51.6500
[18] Wirth M, Tammela T, Cicalese V, et al. Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS)[J]. Eur Urol, 2015, 67(3): 482-491. doi: 10.1016/j.eururo.2014.02.014
[19] Savvidou OD, Bolia IK, Chloros GD, et al. Denosumab: current use in the treatment of primary bone tumors[J]. Orthopedics, 2017, 40(4): 204-210. http://europepmc.org/abstract/MED/28732103
[20] Smith MR, Coleman RE, Klotz L, et al. Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events[J]. Ann Oncology, 2015, 26(2): 368-374. http://cn.bing.com/academic/profile?id=6174661819363f90c34790b890a6c630&encoded=0&v=paper_preview&mkt=zh-cn
[21] Chittenden SJ, Hindorf C, Parker CC, et al. A Phase 1, open-label study of the biodistribution, pharmacokinetics and dosimetry of Radium-223 dichloride (223Ra dichloride) in patients with hormone-refractory prostate cancer and skeletal metastases[J]. J Nucl Med, 2015, 56(9): 1304-1309. doi: 10.2967/jnumed.115.157123
[22] Suominen MI, Fagerlund KM, Rissanen JP, et al. Radium-223 inhibits osseous prostate cancer growth by dual targeting of cancer cells and bone microenvironment in mouse models[J]. Clin Cancer Res, 2017, 23(15): 4335-4346. doi: 10.1158/1078-0432.CCR-16-2955
[23] Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer[J]. N Engl J Med, 2013, 369(3): 213-223. doi: 10.1056/NEJMoa1213755
[24] Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study[J]. Lancet Oncol, 2015, 16(2): 152-160. doi: 10.1016/S1470-2045(14)71205-7
[25] Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer[J]. N Engl J Med, 2017, 377(4): 352-360. doi: 10.1056/NEJMoa1704174
[26] James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy[J]. N Engl J Med, 2017, 377(4): 338-351. doi: 10.1056/NEJMoa1702900
[27] Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy[J]. N Engl J Med, 2014, 371(5): 424-433. doi: 10.1056/NEJMoa1405095
[28] Beer TM, Armstrong AJ, Rathkopf D, et al. Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study[J]. Eur Urol, 2017, 71(2): 151-154. http://www.tandfonline.com/servlet/linkout?suffix=CIT0037&dbid=8&doi=10.1080%2F17425255.2018.1440288&key=27477525
[29] Hussain M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castration resistant prostate cancer[J]. N Engl J Med, 2018, 378(26): 2465-2474. doi: 10.1056/NEJMoa1800536
[30] Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone sensitive prostate cancer[J]. N Engl J Med, 2015, 373(8): 737-746. doi: 10.1056/NEJMoa1503747
[31] James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to frst line long term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial[J]. Lancet, 2016, 387(10024): 1163-1177. doi: 10.1016/S0140-6736(15)01037-5
[32] Wallis CJD, Klaassen Z, Bhindi B, et al. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis[J]. Eur Urol, 2018, 73(6): 834-844. doi: 10.1016/j.eururo.2017.10.002
[33] Al-Batran SE, Hozaeel W, Tauchert FK, et al. The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax)[J]. Ann Oncol, 2015, 26(6): 1244-1248. doi: 10.1093/annonc/mdv129
[34] De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial[J]. Lancet, 2010, 76(9747): 1147-1154. http://cn.bing.com/academic/profile?id=18817b4c6c42963123d2aff69ad20ed0&encoded=0&v=paper_preview&mkt=zh-cn
[35] Eisenberger M, Hardy-Bessard AC, Kim CS, et al. Phase Ⅲ study comparing a reduced dose of cabazitaxel (20 mg/m2) and the currently approved dose (25 mg/m2) in postdocetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA[J]. J Clin Oncol, 2017, 35(28): 3198-3206. doi: 10.1200/JCO.2016.72.1076
[36] Oudard S, Fizazi K, Sengeløv L, et al. Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase Ⅲ trial-FIRSTANA[J]. J Clin Oncol, 2017, 35(28): 3189-3197. doi: 10.1200/JCO.2016.72.1068
[37] Kearns B, Lloyd Jones M, Stevenson M, et al. Cabazitaxel for the second-line treatment of metastatic hormone-refractory prostate cancer: a NICE single technology appraisal[J]. Pharmacoe conomics, 2013, 31(6): 479-488. doi: 10.1007/s40273-013-0050-9
[38] Kaittanis C, Andreou C, Hieronymus H, et al. Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors[J]. J Exp Med, 2018, 215(1): 159-175. doi: 10.1084/jem.20171052
[39] Benesova M, Schafer M, Bauder-Wust U, et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer[J]. J Nucl Med, 2015, 56(6): 914-920. doi: 10.2967/jnumed.114.147413
[40] Kratochwil C, Giesel FL, Eder M, et al.[177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer[J]. Eur J Nucl Med Mol Imaging, 2015, 42(6): 987-988. doi: 10.1007/s00259-014-2978-1
[41] Hofman MS, Violet J, Hicks RJ, et al. 177Lu-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study[J]. Lancet Oncol, 2018, 19(6): 825-833. doi: 10.1016/S1470-2045(18)30198-0
[42] Kim YJ, Kim Y. Therapeutic responses and survival effects of 177Lu-PSMA-617 radioligand therapy in metastatic castrate-resistant prostate cancer: A meta-analysis[J]. Clin Nucl Med, 2018, 43(10): 728-734. doi: 10.1097/RLU.0000000000002210
计量
- 文章访问数: 3677
- HTML全文浏览量: 634
- PDF下载量: 2902
下载:
